IMpassion050 final results show no significant EFS or DFS benefit from adding atezolizumab to HER2-targeted therapy in early ...
Colorectal cancer remains one of the most common and deadliest malignancies worldwide, responsible for well over 900,000 ...
DNA methylation has become one of the hottest targets in modern biomedicine. The chemical tags that adorn cytosine bases ...
The Brighterside of News on MSN
Blood test detects breast cancer more than a year before scans
New research shows a blood test can detect returning breast cancer months to years before scans or symptoms appear.
Countable Labs announces Ancora assays for molecular testing of hematologic malignancy, marking the company's entry into clinical markets.
Global Legionella Testing Market size is expected to be worth around US$ 802.2 Million by 2034 from US$ 358.1 Million in 2024 ...
CompassHER2 pCR identifies clinical and HER2DX predictors of response to neoadjuvant THP in HER2-positive breast cancer.
In HER2-positive breast cancer, treatment outcomes have improved significantly by combining chemotherapy with anti-HER2 therapies such as trastuzumab and pertuzumab.On the other hand, among patients ...
In August 2024, the WHO declared the mpox upsurge in the Democratic Republic of the Congo (DRC), and its spread to ...
The global pharmacogenomics market was valued at USD 5.7 billion in 2025 and is projected to reach USD 15.4 billion by 2035, growing at a CAGR of 10.6%. The global pharmacogenomics market is gaining m ...
As Legionnaires' disease outbreaks spread, discover why cancer patients face severe diagnostic pitfalls and high mortality. Read more now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results